Insmed Inc. (INSM: Quote) announced Monday morning that the FDA has lifted the clinical hold previously placed on ARIKACE in Cystic Fibrosis patients with Pseudomonas lung infections.
Insmed gapped up sharply Monday and has continued to rise, with volume at over a 3-month high. The stock is now up 1.28 at $3.98 and has set over a month and a half high. Insmed has also re-crossed its 50-day moving average.
Click here to receive FREE breaking news email alerts for Insmed Inc and others in your portfolio
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org